With maraviroc as the only CCR5 receptor inhibitor that has been FDA-approved as an anti-HIV med, and another CCR5 receptor inhibitor, vicriviroc, now focusing solely on clinical trials with treatment-naive patients after treatment-experienced trials did not meet endpoints, this class of drugs could use some good news.